Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11351133 | 1.00 | CTSL (0.49) | CTSLPSMB1P2RX7HDAC1HDAC2 | |
| SCHEMBL31151026 | 0.91 | CASP1 (0.52) | CTSLP2RX7 | |
| SCHEMBL11709602 | 0.90 | CTSL (0.49) | CTSLP2RX7HDAC1HDAC2TGM2 | |
| SCHEMBL10898520 | 0.90 | CTSL (0.49) | CTSLP2RX7HDAC1HDAC2TGM2 | |
| SCHEMBL14050011 | 0.90 | HDAC1 (0.55) | CTSLPSMB1HDAC1HDAC2NPC1 | |
| SCHEMBL11867081 | 0.90 | CTSL (0.49) | CTSLP2RX7HDAC1HDAC2TGM2 | |
| SCHEMBL11867075 | 0.90 | CTSL (0.49) | CTSLP2RX7HDAC1HDAC2TGM2 | |
| SCHEMBL9840640 | 0.90 | GAA (0.51) | CTSLRAB9ATGM2 | |
| SCHEMBL1715348 | 0.88 | CTSL (0.57) | CTSLP2RX7CTSB | |
| SCHEMBL7327394 | 0.88 | CTSL (0.57) | CTSLP2RX7CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024105205-A1 | ANTIBODY-DRUG CONJUGATES (A2DCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
| US-5294720-A | Viricides | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1993013066-A1 | CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1993-07-08 | — | — | WO | disclosed |
| EP-0532693-A1 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| WO-1991018866-A2 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-12 | — | — | WO | disclosed |
| US-4244947-A | TREATMENT OF ACROMEGALY AND DIABETES | AYERST MCKENNA AND HARRISON INC. (CA) | 1981-01-13 | — | — | US | disclosed |
| US-3978035-A | POLYPEPTIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DT) | 1976-08-31 | — | — | US | disclosed |
| US-3960828-A | Catalytic hydrogenolysis of protected sulfur containing peptides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | CTSL 303/4885PSMB1 496/4885P2RX7 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.